
# Up to 30% of men with a negative biopsy result actually have cancer<sup>12</sup>

Accurately detecting prostate cancer can sometimes be challenging. Cancer may be present in the areas of your prostate not biopsied.



#### mdxhealth



Xpert One Support is founded on personal attention, responsiveness, and commitment to customer satisfaction.

Our Patient First Promise ensures mdxhealth tests are accessible and affordable for all patients. If you're facing financial challenges, contact an Xpert One Support patient advocate to find the right assistance options for you.



**866-259-7001**Monday - Friday, 6:00AM - 4:30PM PT



patientfirst@mdxhealth.com

#### References

<sup>1</sup>Welch HG, et al. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst. 2007 <sup>2</sup>Pinsky PF, et al. Repeat prostate biopsy in the prostate, lung, colorectal and

<sup>2</sup>Pinsky PF, et al. Repeat prostate biopsy in the prostate, lung, colorectal an ovarian cancer screening trial. BJU Int. 2007

Shen F, et al. Three-dimensional sonography with needle tracking: role in diagnosis and treatment of prostate cancer. J Ultrasound Med. 2008
Cancer Stat Facts: Prostate Cancer. Surveillance, Epidemiology, and End Results (SEER) Program website. Accessed June 2020.
506% NPV for high-grade cancer. Van Neste I., et al. Risk score predicts high

<sup>5</sup>96% NPV for high-grade cancer. Van Neste L, et al. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. Prostate. 2016

Mdxhealth is regulated under the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) as an accredited laboratory to perform high complexity clinical testing. This test was developed, and its performance characteristics determined by Mdxhealth. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined such clearance or approval is not necessary.

CLIA# 05D2033858; CAP# 8015399 IR-BROC-0103-R02









# What to know before your prostate biopsy

Confirm mdx helps identify undetected prostate cancer



### 3 things you should know before having a prostate biopsy<sup>1</sup>

1

Prostate tissue samples taken during your biopsy procedure are reviewed by a pathologist who uses a microscope to examine your tissue for cancer cells.


2

Because the biopsy provides limited information, your urologist may consider additional testing to determine if you're at risk for undetected cancer.

3

A standard prostate biopsy samples less than 1% of the prostate. Your diagnosis is based only on the tissue sampled.<sup>3</sup>

Prostate (lateral [side] view)



## Will your insurance cover Confirm mdx?

Mdxhealth will work directly with your insurance provider to coordinate coverage. \$0 patient responsibility for Medicare. The vast majority of patients are responsible for \$250 or less.

For questions about insurance, contact our Patient Advocate Team.

866-259-7001

patientfirst@mdxhealth.com

# Get the most information possible from your prostate biopsy with Confirm mdx

The Confirm mdx test will help to determine if you are at risk for undetected prostate cancer. The test examines your biopsy tissue at a DNA level to detect cancer-related changes that cannot be seen during a standard microscopic evaluation.

#### Can Confirm mdx determine your risk for undetected cancer?

Confirm mdx will provide you with valuable information about your risk for undetected prostate cancer. A negative Confirm mdx test result will provide you peace of mind and confidence that aggressive cancer was not missed.<sup>5</sup>

Because the test is performed on the existing biopsy samples, **no additional office visit or procedure is required** for your doctor to order Confirm mdx.